source
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchNew data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.BioPharma Dive · 2mo ago↗ source
- Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head testThe results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.BioPharma Dive · 2mo ago↗ source
- Ethyreal starts up with $101M and takes aim at a pair of immune diseasesThe startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.